Imaging of Musculoskeletal Bacterial Infections by [124I]FIAU-PET/CT

Díaz, Luis A.; Foss, Catherine A.; Thornton, Katherine A.; Nimmagadda, Sridhar; Endres, Christopher J.; Uzuner, Ovsev; Seyler, Thorsten M.; Ulrich, Slif D.; Conway, Janet D.; Bettegowda, Chetan; Agrawal, Nishant; Cheong, Ian; Zhang, Xiaosong; Ladenson, Paul W.; Vogelstein, Barry N.; Mont, Michael A.; Zhou, Shibin; Kinzler, Kenneth W.; Vogelstein, Bert; Pomper, Martin G.

doi:10.1371/journal.pone.0001007

Cited by 87 publications

(77 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These ligands allow the non-invasive detection of bacteria or viruses by targeting thymidine kinase (TK), whose substrate is distinct from that of the major human TK. Because those uracil nucleoside derivatives are incorporated into bacteria rather than into inflammatory cells, it should be specific for the infectious process, as shown in a pilot study of musculoskeletal bacterial infection in humans [115].…”

Section: Investigational/experimental Tracersmentioning

confidence: 99%

Prosthetic joint infections: radionuclide state-of-the-art imaging

Gemmel¹,

Wyngaert²,

Love

et al. 2012

Eur J Nucl Med Mol Imaging

170

151

View full text Add to dashboard Cite

Prosthetic joint replacement surgery is performed with increasing frequency. Overall the incidence of prosthetic joint infection (PJI) and subsequently prosthesis revision failure is estimated to be between 1 and 3%. Differentiating infection from aseptic mechanical loosening, which is the most common cause of prosthetic failure, is especially important because of different types of therapeutic management. Despite a thorough patient history, physical examination, multiple diagnostic tests and complex algorithms, differentiating PJI from aseptic loosening remains challenging. Among imaging modalities, radiographs are neither sensitive nor specific and cross-sectional imaging techniques, such as computed tomography and magnetic resonance imaging, are limited by hardware-induced artefacts. Radionuclide imaging reflects functional rather than anatomical changes and is not hampered by the presence of a metallic joint prosthesis. As a result scintigraphy is currently the modality of choice in the investigation of suspected PJI. Unfortunately, there is no true consensus about the gold standard technique since there are several drawbacks and limitations inherent to each modality. Bone scintigraphy (BS) is sensitive for identifying the failed joint replacement, but cannot differentiate between infection and aseptic loosening. Combined bone/gallium scintigraphy (BS/GS) offers modest improvement over BS alone for diagnosing PJI. However, due to a number of drawbacks, BS/GS has generally been superseded by other techniques but it still may have a role in neutropenic patients. Radiolabelled leucocyte scintigraphy remains the gold standard technique for diagnosing neutrophil-mediated processes. It seems to be that combined in vitro labelled leucocyte/bone marrow scintigraphy (LS/BMS), with an accuracy of about 90%, is currently the imaging modality of choice for diagnosing PJI. There are, however, significant limitations using in vitro labelled leucocytes and considerable effort has been devoted to developing alternative radiotracers, such as radiolabelled HIGs, liposomes, antigranulocyte antibodies and fragments, as well as more investigational tracers such as radiolabelled antibiotics, antimicrobial peptides, bacteriophages and thymidine kinase. On the other hand, positron emission tomography (PET) is still growing in the field of PJI imaging with radiotracers such as (18)F-fluorodeoxyglucose (FDG), (18)F-FDG white blood cells and (18)F-fluoride. But unfortunately this superb tomographic technique will only receive full acceptance when specific PET uptake patterns can be successfully developed. The emergence of hybrid modality imaging using integrated single photon emission computed tomography (SPECT) and PET with computed tomography (SPECT/CT and PET/CT) may also have a contributing role for more accurate assessment of joint replacement complications, especially combined with new radiotracers such as (68)Ga and (64)Cu. Finally, in searching for infection-specific tracers, currently there is no such diagnostic agent available.

show abstract

Section: Investigational/experimental Tracersmentioning

confidence: 99%

Prosthetic joint infections: radionuclide state-of-the-art imaging

Gemmel¹,

Wyngaert²,

Love

et al. 2012

Eur J Nucl Med Mol Imaging

170

151

View full text Add to dashboard Cite

show abstract

“…Unfortunately, none of these tracers are specific for bacteria and are therefore unable to distinguish bacterial infection from sterile inflammation. Recent years have seen the development of several PET tracers, including 68 Ga-ubiquicidin and 29-deoxy-29-fluoro-1bD-arabinofuranosyl-5-124 I-iodouracil ( 124 I-FIAU) (9)(10)(11). Of these, 68 Ga-ubiquicidin has shown promise in preclinical studies (11), but further evaluation in multicenter clinical trials is warranted (11,12).…”

mentioning

confidence: 99%

Specific Imaging of Bacterial Infection Using 6″-¹⁸F-Fluoromaltotriose: A Second-Generation PET Tracer Targeting the Maltodextrin Transporter in Bacteria

et al. 2017

View full text Add to dashboard Cite

“…Thus, the "no-effect dose" of FIAU might be conservatively estimated to be on the order of 0.1 mg/kg per administration. [ 124 I]FIAU has been administered to patients for imaging without any adverse effect on hepatic function [108]. Extrapolating from our xenograft experiments, a radiotherapeutic effect is likely to be achieved at doses of FIAU that are orders of magnitude times less than the no-effect FIAU dose in humans.…”

Section: Betr For Gammaherpesvirus-associated Tumormentioning

confidence: 95%

Imaging Virus-Associated Cancer

Fu¹,

Foss²,

Nimmagadda³

et al. 2008

CPD

Self Cite

View full text Add to dashboard Cite

Cancer remains an important and growing health problem. Researchers have made great progress in defining genetic and molecular alterations that contribute to cancer formation and progression. Molecular imaging can identify appropriate patients for targeted cancer therapy and may detect early biochemical changes in tumors during therapy, some of which may have important prognostic implications. Progress in this field continues largely due to a union between molecular genetics and advanced imaging technology. This review details uses of molecular-genetic imaging in the context of tumor-associated viruses. Under certain conditions, and particularly during pharmacologic stimulation, gammaherpesviruses will express genes that enable imaging and therapy in vivo. The techniques discussed are readily translatable to the clinic.

show abstract

Imaging of Musculoskeletal Bacterial Infections by [124I]FIAU-PET/CT

Cited by 87 publications

References 21 publications

Prosthetic joint infections: radionuclide state-of-the-art imaging

Prosthetic joint infections: radionuclide state-of-the-art imaging

Specific Imaging of Bacterial Infection Using 6″-¹⁸F-Fluoromaltotriose: A Second-Generation PET Tracer Targeting the Maltodextrin Transporter in Bacteria

Imaging Virus-Associated Cancer

Contact Info

Product

Resources

About

Imaging of Musculoskeletal Bacterial Infections by [124I]FIAU-PET/CT

Cited by 87 publications

References 21 publications

Prosthetic joint infections: radionuclide state-of-the-art imaging

Prosthetic joint infections: radionuclide state-of-the-art imaging

Specific Imaging of Bacterial Infection Using 6″-18F-Fluoromaltotriose: A Second-Generation PET Tracer Targeting the Maltodextrin Transporter in Bacteria

Imaging Virus-Associated Cancer

Contact Info

Product

Resources

About

Specific Imaging of Bacterial Infection Using 6″-¹⁸F-Fluoromaltotriose: A Second-Generation PET Tracer Targeting the Maltodextrin Transporter in Bacteria